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Objectives Hepatocellular carcinoma (HCC) usually occurs in patients with cirrhosis, but can also develop in noncirrhotic livers.
In the present study we explored associated risk factors for HCC without cirrhosis and compared patient and tumor
characteristics and outcomes in HCC patients with and without underlying cirrhosis.
Methods Patients with HCC diagnosed in the period 2005–2012 in five Dutch academic centers were evaluated. Patients were
categorized according to the presence of cirrhosis on the basis of histology or combined radiological and laboratory features.
Results In total, 19% of the 1221 HCC patients had no underlying cirrhosis. Noncirrhotic HCC patients were more likely to be
female and to have nonalcoholic fatty liver disease or no risk factors for underlying liver disease, and less likely to have hepatitis C
virus or alcohol-related liver disease than did cirrhotic HCC patients. HCCs in noncirrhotic livers were more often unifocal (67 vs.
48%), but tumor size was significantly larger (8 vs. 4 cm). Despite the larger tumors, more patients underwent resection (50 vs.
10%) and overall survival was significantly better than in cirrhotics. In multivariate analyses, absence of cirrhosis [hazard ratio (HR)
0.49, 95% confidence interval (CI) 0.38–0.63] and presence of hepatitis B (HR 0.68, 95% CI 0.51–0.91) were independent
predictors for lower mortality, whereas hepatitis C virus was associated with higher mortality (HR 1.32, 95% CI 1.01–1.65).
Conclusion HCC without cirrhosis was strongly associated with female sex and presence of nonalcoholic fatty liver disease or
no risk factors for underlying liver disease. In absence of cirrhosis, resections were more often performed, with better survival
despite larger tumor size. Eur J Gastroenterol Hepatol 28:352–359
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Introduction
Primary liver cancer is the sixth most common cancer in
the world and the second cause of cancer-related death [1].
Hepatocellular carcinoma (HCC) represents more than
90% of all primary liver cancers and typically occurs in
patients with underlying cirrhosis. Nevertheless, HCC can
also develop in noncirrhotic livers. On the basis of pre-
vious studies, the proportion of HCC in the absence of
cirrhosis varied widely (from 2 to 54%) between various
geographical regions [2–7]. This may be the consequence
of different patterns of underlying risk factors, such as
viral hepatitis, alcohol abuse, and nonalcoholic fatty liver
disease (NAFLD).
Currently, NAFLD is a leading cause of chronic liver
disease in the Western countries and its prevalence is
expected to increase further [8,9]. There is emerging evi-
dence that presence of NAFLD and features of metabolic
syndrome are associated with HCC [10–15]. Increased
HCC risk seems to affect especially those with cirrhosis.
Nevertheless, it has recently been demonstrated that in
noncirrhotic livers, presence of NAFLD, and especially
nonalcoholic steatohepatitis, is strongly associated with
HCC [13,16–18]. Furthermore, steatosis is often present as
a cofactor in patients with other risk factors for underlying
liver disease [19].
The severity of the underlying liver disease has a great
impact on treatment decisions and prognosis in HCC
patients: presence of cirrhosis and resulting impaired liver
function may limit surgical and nonsurgical options. In
contrast, absence of cirrhosis could favor use of surgical
treatment with curative intent [6,20,21]. Available data
also suggest that etiology of underlying liver disease in
HCC patients may influence outcomes [22].
In the present study we explored the prevalence of HCC
in absence of cirrhosis and investigated associated risk
factors in a large cohort of HCC patients. Furthermore, we
compared patient and tumor characteristics as well as
outcomes in HCC patients with and without underlying
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cirrhosis and with various causes of underlying liver
disease.
Methods
All patients with an HCC diagnosis in the period
2005–2012 in five major Dutch academic centers were
evaluated. Diagnosis of HCC was based on AASLD 2005
and 2011 guideline criteria [23,24]. Data on the influence
of HCC surveillance in the same cohort have recently been
reported [25]. Collected data were obtained from (elec-
tronic) medical records. Extensive efforts were made to
clarify all missing data – for example, by contacting
patients, or referring hospitals or general practitioners.
Patients were categorized according to the presence or
absence of cirrhosis. Patients were included in the ‘no
cirrhosis’ group on the basis of the following criteria as
essentially proposed by El-Serag et al. [26]: (A) histology
without cirrhosis either in biopsy within 1 year of HCC
diagnosis or in a resection specimen in combination with
absence of radiological features of cirrhosis, or (B) (in
absence of liver histology) all three of the following cri-
teria: (1) an aspartate aminotransferase to platelet ratio
index less than or equal to 1, (2) two of the following three
laboratory tests within normal range: (a) albumin greater
than 35 g/l, (b) platelet counts greater than 200× 109/l, (c)
international normalized ratio less than 1.1, and (3)
absence of radiological features of cirrhosis. The aspartate
aminotransferase to platelet ratio index score was calcu-
lated using the following formula: (aspartate amino-
transferase/upper limit of normal)/(platelet count× 100)
[27]. Patients who had histology demonstrating cirrhosis
or (in absence of histology) clear radiological features of
cirrhosis and/or did not fulfill the above mentioned criteria
for the ‘no cirrhosis’ group were included in the
‘cirrhosis’ group.
Information was collected on the cause of underlying
liver disease: (a) alcohol-related liver disease (defined as a
history of average alcohol use more than or equal to three
alcoholic drinks/day [28]), (b) hepatitis B virus (HBV), (c)
hepatitis C virus (HCV), (d) hemochromatosis, (e) NAFLD
(defined as steatosis greater than 5%, steatohepatitis on
liver biopsy, or presence of metabolic syndrome in the
absence of other risk factors for chronic liver disease, such
as alcohol abuse), (f) others, or (g) absence of any risk
factors for underlying liver disease. Finally, data on tumor
characteristics [e.g. number of tumor lesions, maximum
diameter of the largest tumor lesion, and tumor stage
according to Barcelona Clinic Liver Cancer (BCLC) sta-
ging system], laboratory values at time of diagnosis,
applied treatment(s), and survival data were obtained for
each patient. Patients were categorized into treatment
groups on the basis of application of surgical therapy
(resection or transplantation), radiofrequency ablation
(RFA), transcatheter arterial chemoembolization (TACE)
or transarterial radioembolization (TARE), systemic ther-
apy (sorafenib) or best supportive care. Patients under-
going sequential therapy appertaining to two or more
treatment groups were included in the treatment group
that was presumed to have most impact on outcome. In
case of RFA and subsequently TACE with at least a
1 month interval, patients were included in the RFA group.
When a combination of RFA and TACE was performed
within a 1 month interval, patients were included in the
TACE group.
This study was conducted in agreement with the ethical
guidelines of the Declaration of Helsinki, and analyses
were carried out with institutional medical ethical consent,
in an anonymized database.
Statistical analysis
Continuous data were expressed as means and SDs or, in
case of a nonparametric distribution, as medians and
ranges, and discrete variables were expressed as absolute
and relative frequencies. Independent samples t-test, one-
way analysis of variance, Mann–Whitney U or
Kruskal–Wallis tests were applied to compare continuous
data in the ‘cirrhosis’ versus ‘no cirrhosis’ groups. Post-hoc
analyses using analysis of variance with Bonferroni cor-
rection were performed to compare the five major etiology
groups. Categorical variables were compared with
Pearson’s χ2 or Fisher’s exact tests.
Univariate and multivariate logistic regression analyses
were performed to evaluate patient characteristics (i.e. sex,
age, and etiology of underlying liver disease) associated
with risk of HCC in absence of cirrhosis.
Survival time was calculated from date of diagnosis to
date of death or end of follow-up (latest: end of study 1
January 2013). The Kaplan–Meier survival curves and log-
rank tests were used to compare survival rates between the
cirrhotic and noncirrhotic patients in the total group and
between the five major etiology groups: HBV, HCV,
alcohol-related liver disease, NAFLD, and absence of risk
factors for underlying liver disease. Survival between cir-
rhotic and noncirrhotic patients was also evaluated sepa-
rately in the different treatment groups, except for RFA as
this treatment was almost exclusively performed in cir-
rhotic patients. Possible predictors for overall mortality
were tested using univariate and multivariate Cox pro-
portional hazard regression. Besides the presence of cir-
rhosis and etiology of underlying liver disease, sex, age,
tumor size, number of tumor lesions, BCLC stage, and year
of HCC diagnosis were included. Factors with a P-value of
less than 0.1 in univariate analyses were included in sub-
sequent multivariate analyses. A two-sided P-value of less
than 0.05 was considered statistically significant. Statistical
analysis was performed using IBM SPSS statistics (version
20.0; IBM Corp., Armonk, New York, USA).
Results
In the period January 2005–December 2012, 1290 HCC
patients were under care in five academic hospitals (i.e.
∼ 60% of all Dutch HCC patients in this period [29]).
After the exclusion of 69 patients because of missing data,
1221 patients (95%) were included in this study.
Patient and clinical characteristics in the ‘cirrhosis’
versus ‘no cirrhosis’ groups
In total, 983 of the 1221 included patients (81%) had
underlying cirrhosis, without change during the study
period. In 238 patients (19%) no cirrhosis was present:
fibrosis grade was less than or equal to F2 in 148 patients
(62% of all noncirrhotic patients), F3 in 19 (8%), and
unknown in 71 (30%). Patient characteristics of all HCC
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patients, and separately for the ‘cirrhosis’ and ‘no cir-
rhosis’ groups, are given in Table 1. Median age at the
time of HCC diagnosis was 63 years (range: 8–91 years)
and did not differ between the two groups. Proportion of
men was significantly lower in noncirrhotic patients than
in cirrhotic patients (66 vs. 79%; P< 0.001). BMI was also
significantly lower in noncirrhotic than in cirrhotic
patients (25.4 vs. 27.1 kg/m2, P<0.001). Furthermore,
presence of NAFLD (12 vs. 28%) and absence of risk
factors for underlying liver disease (idiopathic HCC; 7 vs.
30%) were more common in patients without cirrhosis
than in those with cirrhosis. On the other hand, cirrhotic
HCC patients were more likely to have alcohol-related
liver disease (32 vs. 16%) and HCV (24 vs. 6%). The
contribution of HBV-related HCC was similar in the ‘cir-
rhosis’ and ‘no cirrhosis’ groups (16 vs. 15%) (Table 1).
Of the 37 patients with hemochromatosis (29 and eight in
the ‘cirrhosis’ and ‘no cirrhosis’ groups, respectively),
diagnosis was based on positive genetic testing in 41%,
whereas in 59% of patients diagnosis was based on
laboratory features (i.e. highly increased ferritin and high
iron saturation) and typical histopathological character-
istics of hemochromatosis.
Risk factors for HCC in absence of cirrhosis
In multivariate analysis, absence of risk factors for
underlying chronic liver disease [odds ratio (OR): 4.28,
95% confidence interval (CI) 2.58–7.10], presence of
NAFLD (OR: 2.59, 95% CI 1.58–4.26), and female sex
(OR: 1.44, 95% CI 1.01–2.05) were independent risk
factors for HCC in absence of cirrhosis. In contrast, pre-
sence of alcohol-related liver disease (OR: 0.56, 95% CI
0.33–0.93) and HCV (OR: 0.25, 95% CI 0.13–0.48) were
less often present in HCC patients with noncirrhotic livers
(Table 2).
Tumor characteristics in the ‘cirrhosis’ versus ‘no
cirrhosis’ groups
Number of tumor lesions differed significantly between the
cirrhotic and noncirrhotic patients: unifocal HCC was
significantly more common in patients without cirrhosis
(48 vs. 67%), whereas proportion of multifocal or diffuse
HCC was higher in patients with cirrhosis (32 vs. 23%)
(P<0.001) (Table 3). Nevertheless, tumor size was sig-
nificantly larger in noncirrhotic patients than in cirrhotic
patients (median tumor size: 8 vs. 4 cm; P< 0.001). In
patients with cirrhosis, HCC was detected at an earlier
tumor stage (BCLC 0 and A combined: 38 vs. 19%) than
in patients without cirrhosis. α-Fetoprotein level was sig-
nificantly higher in patients with cirrhosis than in those
without cirrhosis (35 vs. 10 µg/l; P<0.001) (Table 3).
Treatment in the ‘cirrhosis’ versus ‘no cirrhosis’ groups
Despite the larger tumor size in patients without cirrhosis,
overall proportion of patients who received surgical ther-
apy was higher than in cirrhotic patients (53 vs. 22%):
resection was more often performed in patients without
cirrhosis (50 vs. 10%), whereas more patients with cir-
rhosis underwent transplantation (12 vs. 2%) (Table 3).
RFA (15 vs. 2%) and TACE/TARE (18 vs. 13%) were also
more often performed in cirrhotic patients. Proportion of
patients who received sorafenib was higher in patients
without cirrhosis (14 vs. 8%). Almost one-third of the
cirrhotic patients received only best supportive care,
whereas this was the case only in 15% of the noncirrhotic
patients (Table 3).
Survival in ‘cirrhosis’ versus ‘no cirrhosis’ groups
Data on vital status at the end of the study were available
in 1148 patients (94% of all included patients). Median
Table 1. Patient characteristics of 1221 cases with hepatocellular carcinoma subdivided according to presence or absence of cirrhosis
Total group Cirrhosis No cirrhosis P-valuea
Patient number 1221 (100) 983 (81) 238 (19)
Male sex 936 (77) 779 (79) 157 (66) < 0.001
Age at HCC diagnosis 63 (8–91) 63 (8–91) 65 (11–88) 0.514
BMI [mean (SD)] 26.7 (5.0) 27.1 (5.0) 25.4 (4.7) < 0.001
Etiology < 0.001
Alcohol 349 (29) 312 (32) 37 (16)
Chronic viral hepatitis
HBV 197 (16) 162 (16) 35 (15)
HCV 249 (20) 236 (24) 13 (6)
Coinfection 19 (2) 18 (2) 1 (<1)
Hemochromatosis 37 (3) 29 (3) 8 (3)
NAFLD 181 (15) 114 (12) 67 (28)
Others 43 (3) 39 (4) 4 (2)
No risk factors known 146 (12) 73 (7) 73 (30)
ALT (U/l) 47 (4–1193) 49 (4–1193) 39 (8–712) < 0.001
AST (U/l) 66 (14–8678) 71 (15–8678) 46 (14–1344) < 0.001
Albumin 38 (13–62) 37 (13–58) 43 (16–62) < 0.001
Platelets 146 (8–985) 125 (8–985) 259 (62–724) < 0.001
INR 1.1 (0.8–2.9) 1.2 (0.8–2.9) 1.0 (0.8–1.8) < 0.001
PT 13.9 (9.7–36.7) 14.3 (10.0–36.2) 12.3 (9.7–36.7) < 0.001
APRI 1.6 (0.1–304) 2.0 (0.1–304) 0.6 (0.1–32) < 0.001
MELD score 9 (6–33) 10 (6–33) 7 (6–29) < 0.001
Results indicate numbers and, between brackets, percentages. Continuous variables reported as medians and, between brackets, ranges unless otherwise indicated.
Significant P-values are in bold.
ALT, alanine transaminase; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransaminase; coinfection, HBV+HCV infection; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model For End-Stage Liver Disease; NAFLD, nonalcoholic fatty
liver disease; PT, prothrombin time.
aP-value applies to the ‘cirrhosis’ versus ‘no cirrhosis’ groups.
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follow-up for both groups was 12 months (range
0.1–95 months). Follow-up time was significantly longer in
noncirrhotics than in cirrhotics (15 vs. 11 months;
P= 0.001). The 1-, 3-, and 5-year survival rates were sig-
nificantly higher in noncirrhotic patients than in cirrhotic
patients (72, 49, and 43% vs. 56, 33, and 29%, respec-
tively) (Fig. 1, log-rank test P<0.001). In multivariate
analysis, absence of cirrhosis was an independent predictor
for lower overall mortality [hazard ratio (HR) 0.49, 95%
CI 0.38–0.63], after adjusting for age, etiology of under-
lying liver disease, tumor size, number of tumor lesions,
and BCLC stage (Table 4). An age of less than or equal to
62 years (HR 0.76, 95% CI 0.63–0.91) and presence of
HBV (HR 0.68, 95% CI 0.51–0.91) were also associated
with lower mortality. In contrast, presence of HCV (HR
1.32, 95% CI 1.01–1.65), larger tumor size (HR 1.07,
95% CI 1.04–1.09), multifocal or diffuse HCC (HR 1.64,
95% CI 1.31–2.05), and a more advanced BCLC stage
were independent predictors for higher overall mortality
(Table 4).
In patients who underwent surgical treatment, absence
of cirrhosis (HR 0.38, 95% CI 0.21–0.71) and treatment
Table 2. Association between patient characteristics and the occurrence of hepatocellular carcinoma in absence of cirrhosis: univariate and
multivariate logistic regression analysis
Univariate analysis Multivariate analysis
Variables Patients (n=1221) OR 95% CI P-value OR 95% CI
Sex
Male 936 (77) Ref. – < 0.001 Ref. –
Female 285 (23) 1.97 1.45–2.68 1.44 1.01–2.05
Age at HCC diagnosis (years)
≤62 585 (48) 0.81 0.61–1.08 0.137 1.05 0.75–1.45
>62 636 (52) Ref. – Ref. –
Etiology
Alcohol 349 (29) 0.55 0.33–0.91 0.56 0.33–0.93
Hepatitis B 197 (16) Ref. – Ref. –
Hepatitis C 249 (20) 0.26 0.13–0.50 0.25 0.13–0.48
Coinfection 19 (2) 0.26 0.03–1.99 < 0.001 0.26 0.03–2.03
Hemochromatosis 37 (3) 1.28 0.54–3.03 1.34 0.56–3.24
NAFLD 181 (15) 2.72 1.69–4.37 2.59 1.58–4.26
Other 43 (3) 0.48 0.16–1.42 0.41 0.14–1.24
No risk factors known 146 (12) 4.63 2.84–7.55 4.28 2.58–7.10
Values in parentheses are percentages.
Significant odds ratios, 95% CIs and P-values are in bold.
CI, confidence interval; coinfection, hepatitis B+hepatitis C infection; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio.
Table 3. Tumor characteristics of 1221 patients with hepatocellular carcinoma subdivided according to presence or absence of cirrhosis
Total group Cirrhosis No cirrhosis P-valuea
Patient number 1221 (100) 983 (81) 238 (19)
Number of lesions < 0.001
1 632 (52) 473 (48) 159 (67)
2 152 (12) 132 (14) 20 (8)
3 68 (6) 63 (6) 5 (2)
Multifocal/diffuse 369 (30) 315 (32) 54 (23)
Tumor size (cm) 5 (1–26) 4 (1–26) 8 (1–26) < 0.001
BCLC stage < 0.001
0 75 (6) 72 (7) 3 (1)
A 345 (28) 301 (31) 44 (18)
B 406 (33) 274 (28) 132 (56)
C 299 (25) 247 (25) 52 (22)
D 96 (8) 89 (9) 7 (3)
α-Fetoprotein (µg/l) 29 (1–2.7×106) 35 (1–1.8×106) 10 (1–2.7×106) < 0.001
Treatments < 0.001
Surgical therapy 341 (28) 215 (22) 126 (53)
Resection 214 (18) 95 (10) 119 (50)
Transplantation 120 (10) 116 (12) 4 (2)
Both 6 (<1) 4 (<1) 2 (1)
RFAb 149 (12) 145 (15) 4 (2)
TACE/TAREc 207 (17) 176 (18) 31 (13)
Systemic therapy 118 (10) 85 (8) 33 (14)
Best supportive care 351 (29) 314 (32) 36 (15)
Unknown 55 (4) 48 (5) 8 (3)
Results indicate numbers and, between brackets, percentages. Continuous variables reported as medians and, between brackets, ranges.
Significant P-values are in bold.
BCLC stage, tumor stage according Barcelona Clinic Liver Cancer staging system; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; TARE,
transarterial radioembolization.
aP-value applies to ‘cirrhosis’ versus ‘no cirrhosis’ groups.
bThirteen patients received RFA and subsequently TACE with more than 1 month interval.
cIn 31 patients a combination of TACE and RFA within a 1 month interval was performed as initial therapy.
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with transplantation instead of resection (HR 0.24, 95%
CI 0.13–0.42) were both independently associated with
lower overall mortality, after adjustment for etiology of
underlying liver disease, tumor size, number of tumor
lesions, and BCLC stage. In patients who received TACE
or sorafenib treatment, survival was not different between
cirrhotic and noncirrhotic patients (results not shown).
RFA was almost exclusively performed in cirrhotic
patients and therefore impact of cirrhosis could not be
evaluated.
Patient and clinical characteristics and outcome in
relation to etiology of underlying liver disease
Of all the included patients (n=1221), 29% had underlying
alcohol-related liver disease, 20% had HCV, 16% had
HBV, 15% had NAFLD, and 12% had no risk factors.
Patient characteristics were significantly different between
the five major etiology groups (in total 1122 patients,
included in the following analyses) (Supplementary Table 1,
Supplemental digital content 1, http://links.lww.com/EJGH/
A61). Patients with HBV or HCV who developed HCC
were significantly younger than patients with alcohol-related
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Fig. 1. Observed survival of patients with hepatocellular carcinoma in the
‘cirrhosis’ group (solid line) and ‘no cirrhosis’ group (dotted line)
(Kaplan–Meier survival curve; log-rank P<0.001).
Table 4. Relation between patient/tumor characteristics and mortality in 1148 patients with hepatocellular carcinoma: univariate and multivariate Cox
proportional hazard regression analyses
Univariate analysis Multivariate analysis
Variables Patients (n=1148) HR 95% CI P-value HR 95% CI
Presence of cirrhosis
Yes 919 (80) Ref. – < 0.001 Ref. –
No 229 (20) 0.67 0.55–0.82 0.49 0.38–0.63
Sex
Male 879 (77) Ref. – 0.46
Female 269 (23) 0.94 0.79–1.12
Age at HCC diagnosis (years)
≤62 543 (47) 0.77 0.67–0.90 0.001 0.76 0.63–0.91
>62 605 (53) Ref. – Ref. –
Etiology
Alcohol 334 (29) Ref. – Ref. –
Hepatitis B 179 (16) 0.59 0.46–0.75 0.68 0.51–0.91
Hepatitis C 232 (20) 0.84 0.68–1.03 1.32 1.01–1.65
Coinfection 18 (2) 0.44 0.22–0.89 0.001 0.71 0.33–1.52
Hemochromatosis 36 (3) 0.96 0.63–1.47 0.94 0.57–1.56
NAFLD 175 (15) 0.90 0.71–1.13 0.92 0.70–1.21
Other 40 (3) 0.81 0.53–1.25 1.30 0.79–2.12
No risk factors known 134 (12) 0.44 0.22–0.89 0.70 0.32–1.49
Tumor sizea 1008 (88) 1.08 1.06–1.09 < 0.001 1.07 1.04–1.09
Number of tumor lesions
1 602 (53) Ref. – < 0.001 Ref. –
2 142 (12) 1.24 0.97–1.59 1.27 0.98–1.65
3 66 (6) 1.55 1.12–2.15 1.29 0.92–1.83
Multifocal (>3)/diffuse 338 (29) 3.93 3.31–4.66 1.64 1.31–2.05
BCLC stage
0 73 (7) Ref. – Ref. –
A 334 (29) 1.18 0.77–1.82 < 0.001 1.09 0.70–1.71
B 389 (34) 2.79 1.85–4.22 1.98 1.24–3.17
C 268 (23) 8.07 5.32–12.24 4.46 2.71–7.34
D 84 (7) 10.08 6.38–15.94 7.87 4.75–13.06
Year of HCC diagnosis
2005 78 (7) 1.06 0.72–1.57
2006 81 (7) 0.81 0.54–1.21
2007 107 (9) 0.83 0.56–1.21
2008 155 (14) 1.08 0.76–1.54 0.15
2009 170 (15) 1.10 0.77–1.55
2010 187 (16) 1.21 0.86–1.71
2011 197 (17) 1.11 0.78–1.59
2012 173 (15) Ref. –
Values in parentheses are percentages.
Significant hazard ratios, 95% CIs and P-values are in bold.
CI, confidence interval; BCLC stage, tumor stage according Barcelona Clinic Liver Cancer staging system; coinfection, hepatitis B+hepatitis C infection; HR, hazard ratio;
NAFLD, nonalcoholic fatty liver disease.
aMissing values: n=140.
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age: 57 and 59 years vs. 65, 67, and 68 years, respectively).
Furthermore, female sex was significantly more frequent in
patients with NAFLD (34%) or with no risk factors (42%)
than in patients with HBV (15%), HCV (21%), or alcohol-
related liver disease (15%). BMI was significantly higher in
patients with alcohol-related or NAFLD-related HCC (mean
BMI 27.8 and 28.9 kg/m2, respectively) than in patients with
HBV (25.8 kg/m2), HCV (26.4 kg/m2), or absence of risk
factors (24.2 kg/m2) (Supplementary Table 1, Supplemental
digital content 1, http://links.lww.com/EJGH/A61).
Alcohol-related HCCs were significantly more often
multifocal or diffuse (38%) than HCCs in patients with
HCV, HBV, NAFLD, or no risk factors (range: 24–30%).
Furthermore, tumor size was significantly larger in absence
of risk factors (9 cm) and smaller in HCV patients (3 cm)
than in patients with HBV (4 cm), alcohol-related liver
disease (5 cm), or NAFLD (6 cm). BCLC tumor stage was
also significantly more advanced in absence of risk factors
(BCLC 0 and A combined: 12%) than in HCC patients
with other disease etiology (for HBV-related, HCV-
related, alcohol-related, or NAFLD-related HCC: BCLC
0 and A combined in 42, 50, 31, and 25%, respectively).
Median α-fetoprotein levels were not significantly different
in the various etiology groups (Supplementary Table 2,
Supplemental digital content 2, http://links.lww.com/
EJGH/A62).
Applied treatments differed significantly between the
various etiology groups (P<0.001) (Supplementary
Table 2, Supplemental digital content 2, http://links.lww.
com/EJGH/A62). The proportion of patients who received
(potentially curative) surgical therapy in general was sig-
nificantly lower in HCC patients with alcohol-related liver
disease (18%) than in patients with HBV, HCV, NAFLD,
or absence or risk factors who were treated with surgical
therapy in 34, 30, 31, and 33% of cases, respectively.
Proportion of patients who underwent resection was sig-
nificantly higher in case of HBV (22%), NAFLD (25%), or
absence of risk factors (27%) than in patients with HCV
(14%) or alcohol-related liver disease (8%). In addition,
patients with HBV, HCV, or alcohol-related liver disease
received significantly more often a liver transplant (11, 15,
and 10%, respectively) than did patients with NAFLD or
no risk factors (6 and 5%, respectively). RFA was most
frequently applied in HCV-related HCC (20%), whereas
only 3% of patients without risk factors and 8% of
patients with NAFLD received RFA. Proportion of
patients who received TACE/TARE ranged between 12
and 20% in the different etiology groups. Furthermore,
HCV patients were significantly less often treated with
sorafenib (4%) than were patients with HBV, NAFLD,
alcohol-related liver disease, or absence of risk factors (9,
11, 12, and 16%, respectively) (Supplementary Table 2,
Supplemental digital content 2, http://links.lww.com/
EJGH/A62).
Survival rates differed significantly between the five
major etiology groups (Fig. 2, log-rank test P<0.001). In
univariate analysis, survival was significantly longer in
HCC patients with HBV (HR 0.59, 95% CI 0.46–0.75,
reference group: patients with alcohol-related liver disease)
than in the other four etiology groups. Survival rates
between the other etiology groups did not differ. As
mentioned earlier, in multivariate analyses, presence of
HBV (HR 0.68, 95% CI 0.51–0.91) was associated with
lower mortality. In contrast, presence of HCV (HR 1.32,
95% CI 1.01–1.65) was an independent predictor for
higher overall mortality (Table 4).
Discussion
This study showed that absence of risk factors for under-
lying liver disease, presence of NAFLD, and female sex
were independently associated with HCC in noncirrhotic
livers. It has previously been reported that patients who
develop HCC in a noncirrhotic liver are younger and that
there is a female predominance, although this was not
confirmed in other studies [3,6,17]. Despite the larger
tumor size and more advanced BCLC tumor stage in HCC
patients without cirrhosis, resections were more often
performed and survival was significantly better than in
cirrhotic patients. In addition, in multivariate analyses,
absence of cirrhosis was an independent predictor of
longer survival. To the best of our knowledge, the current
work represents the largest study assessing the impact of
cirrhosis on outcome in an unselected group of cirrhotic
and noncirrhotic HCC patients.
Recently, a large cohort study of HCC patients from
Germany was published [30]. In line with the results of the
current study, cirrhosis was present in 81% of cases and
survival was significantly better in noncirrhotic patients.
Survival benefit in HCC patients with noncirrhotic livers
was also reported in two older studies with cohorts of
unselected HCC patients [31,32]. Another study, pub-
lished in 2005, reported only significant survival differ-
ences between patients with compensated liver disease and
those with decompensated cirrhosis (Child–Pugh B or C)
[33]. Finally, two other recent studies did not find differ-
ences in survival rates between cirrhotic and noncirrhotic
HCC patients, despite the fact that presence of liver cir-
rhosis strongly affected HCC treatment choices [17,34].
Consistent with our findings, resection was more often



















































Fig. 2. Observed survival of patients with hepatocellular carcinoma with
underlying hepatitis B (line with open circles), NAFLD (line with solid triangles),
hepatitis C (line with solid squares), absence of risk factors (line with solid
circles), or alcohol-related liver disease (line with crosses) (Kaplan–Meier
survival curve; log-rank P<0.001). NAFLD, nonalcoholic fatty liver disease.
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more often received other treatment modalities. In addi-
tion, several studies comparing survival between cirrhotics
and noncirrhotics in specific subgroups – for example,
after HCC resection – reported that overall and disease-
free survivals were significantly better in noncirrhotics [6].
Survival benefit in the total group of noncirrhotic patients
may be related to the fact that (potentially curative) sur-
gical therapy was more frequently performed leading to a
better outcome. Interestingly, in the current report, trans-
plantation appeared to be associated with better outcome
than resection, although patient numbers in the trans-
plantation group were rather small and definite conclu-
sions could not be drawn.
In line with results of previous studies [4,6,17,30,35],
causes for underlying liver disease in cirrhotic and non-
cirrhotic HCC patients were different in our study.
Alcohol abuse and viral hepatitis were the most important
underlying causes in cirrhotic patients, whereas NAFLD
was often present in HCC patients with a noncirrhotic
liver. Furthermore, a significant number of noncirrhotic
HCC patients proved to have no underlying risk factors
despite extensive analyses. The hepatocarcinogenetic
pathway of HCC might differ between cirrhotic and
noncirrhotic livers, but exact mechanisms are still unclear.
In patients with HCV or alcohol-related liver disease, cir-
rhosis appears to be a prerequisite for HCC development.
HBV, on the other hand, could also exert a direct onco-
genic effect regardless of presence of cirrhosis. HBV gen-
ome integration can lead to host DNA microdeletions and
aberrant function of growth regulatory genes in the
hepatocyte. In patients with NAFLD, it is thought that
oxidative stress (as a results of increased intrahepatic fatty
acid levels) may play an important role in the development
of hepatocellular damage and HCC development [36].
One interesting finding of the current study is that there
are significant differences in applied treatment modalities
between patients with various etiologies of underlying liver
disease with potential impact on survival. Some previous
studies have suggested that cause of underlying liver dis-
ease could affect survival, but other studies were not able
to confirm this [22,37–39]. In our study, resection was
more often applied in patients with HBV, NAFLD, or
absence of underlying risk factors for chronic liver disease.
In contrast, RFA was most often performed in case of
HCV. Moreover, presence of HBV was an independent
predictor for lower mortality, whereas presence of HCV
was associated with higher mortality. A potential expla-
nation for these findings could be that patients with HBV
more often developed HCC before progression to cir-
rhosis, with a large proportion of solitary lesions. In
addition, differences in efficacy of prior antiviral treatment
for HBV and HCV could have contributed to these results
obtained in a period before introduction of direct-acting
anti-HCV agents.
An earlier cross-sectional study in the USA veterans
showed that NAFLD and features of metabolic syndrome
(hypertension and diabetes) were strongly associated with
HCC development in absence of cirrhosis, whereas non-
cirrhotic HCC patients were less likely to have HCV or
alcohol-related liver disease [26]. These results are in line
with our findings, although the proportion of noncirrhotic
patients was lower in that study (between 3 and 16%) than
in our study. A potential explanation for this difference
could be the fact that almost exclusively males were
included in the USA veterans study. Unfortunately, details
of metabolic syndrome, except BMI values, were not
available in the current study. Furthermore, BMI values in
our study were not corrected for presence of ascites [40].
Findings of our study are inherently limited by the ret-
rospective study design. In addition, only patients who
were diagnosed or referred to one of the five major Dutch
academic centers were included. HCC patients with a very
poor prognosis were possibly not referred and thus not
included in the current cohort. Furthermore, the term
‘noncirrhotic’ involves a heterogeneous group of condi-
tions ranging from chronic hepatitis with stage III fibrosis
to a morphologically healthy liver. Moreover, it may also
be difficult to differentiate F3 and F4 on the basis of liver
biopsy, especially in case of macronodular cirrhosis.
Conclusion
In this large cohort of HCC patients in the Netherlands,
presence of HCC without cirrhosis was strongly associated
with absence of risk factors for underlying liver disease,
presence of NAFLD, and female sex. In absence of cir-
rhosis, resections were more often performed, despite lar-
ger tumor size. Survival in noncirrhotic patients was
significantly better compared with those with liver
cirrhosis.
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